Our results indicate that lapatinib resistance was augmented by hyperglycemia, and the impeded drug response was partially alleviated by combining lapatinib with DAPT, highlighting the potential value of the combined drug regimen as a therapeutic strategy for treating HER2-positive breast cancer patients with hyperglycemia. This evidence concerns the gene ERBB2 and breast carcinoma.